| Snowflake Score | |
|---|---|
| Valuation | 1/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
6657 Stock Overview
Energenesis Biomedical CO.,LTD. operates in the biomedicine industry in Taiwan.
Energenesis BiomedicalLTD Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | NT$31.60 |
| 52 Week High | NT$60.50 |
| 52 Week Low | NT$30.90 |
| Beta | 0.72 |
| 1 Month Change | -25.47% |
| 3 Month Change | -25.82% |
| 1 Year Change | -40.49% |
| 3 Year Change | -24.94% |
| 5 Year Change | n/a |
| Change since IPO | 1.93% |
Recent News & Updates
We Think Energenesis BiomedicalLTD (GTSM:6657) Can Easily Afford To Drive Business Growth
Just because a business does not make any money, does not mean that the stock will go down. For example, biotech and...
Shareholder Returns
| 6657 | TW Biotechs | TW Market | |
|---|---|---|---|
| 7D | -6.4% | -2.8% | -0.8% |
| 1Y | -40.5% | 6.7% | 4.2% |
Return vs Industry: 6657 underperformed the TW Biotechs industry which returned 6.7% over the past year.
Return vs Market: 6657 underperformed the TW Market which returned 4.2% over the past year.
Price Volatility
| 6657 volatility | |
|---|---|
| 6657 Average Weekly Movement | 5.3% |
| Biotechs Industry Average Movement | 5.3% |
| Market Average Movement | 4.6% |
| 10% most volatile stocks in TW Market | 8.3% |
| 10% least volatile stocks in TW Market | 2.1% |
Stable Share Price: 6657 is not significantly more volatile than the rest of TW stocks over the past 3 months, typically moving +/- 5% a week.
Volatility Over Time: 6657's weekly volatility (5%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2012 | 36 | Han-min Chen | https://www.energenesis-biomedical.com |
Energenesis Biomedical CO.,LTD. operates in the biomedicine industry in Taiwan. It provides ENERGI-F703, which is Phase II clinical trial for use in treatment of diabetic foot ulcers; ENERGI-F701, a topical tonic for the treatment of alopecia that is in Phase II clinical trial; ENERGI-F711, a burn cream; ENERGI-F702 to treat metabolic diseases; ENERGI-F704 for the treatment of inflammatory bowel disease; ENERGI-F708 for asthma treatment; ENERGI-F705 for Parkinson's disease control; ENERGI-F707 for the treatment of mitochondria deficiency; ENERGI-F706 to treat cachexia; ENERGI-F709, a vaccine adjuvant; and ENERGI-F710 for blood phosphate control.
Energenesis BiomedicalLTD Fundamentals Summary
| 6657 fundamental statistics | |
|---|---|
| Market Cap | NT$2.10b |
| Earnings (TTM) | -NT$120.24m |
| Revenue (TTM) | NT$7.49m |
280.8x
P/S Ratio-17.5x
P/E RatioIs 6657 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 6657 income statement (TTM) | |
|---|---|
| Revenue | NT$7.49m |
| Cost of Revenue | NT$2.13m |
| Gross Profit | NT$5.36m |
| Other Expenses | NT$125.60m |
| Earnings | -NT$120.24m |
Last Reported Earnings
Dec 31, 2021
Next Earnings Date
n/a
| Earnings per share (EPS) | -1.81 |
| Gross Margin | 71.56% |
| Net Profit Margin | -1,605.50% |
| Debt/Equity Ratio | 0% |
How did 6657 perform over the long term?
See historical performance and comparisonValuation
Is Energenesis BiomedicalLTD undervalued compared to its fair value and its price relative to the market?
Valuation Score
1/6Valuation Score 1/6
Below Fair Value
Significantly Below Fair Value
PE vs Industry
PE vs Market
PEG Ratio
PB vs Industry
2.47x
Price to Book (PB) ratio
Share Price vs. Fair Value
Below Fair Value: Insufficient data to calculate 6657's fair value for valuation analysis.
Significantly Below Fair Value: Insufficient data to calculate 6657's fair value for valuation analysis.
Price To Earnings Ratio
PE vs Industry: 6657 is unprofitable, so we can't compare its PE Ratio to the TW Biotechs industry average.
PE vs Market: 6657 is unprofitable, so we can't compare its PE Ratio to the TW market.
Price to Earnings Growth Ratio
PEG Ratio: Insufficient data to calculate 6657's PEG Ratio to determine if it is good value.
Price to Book Ratio
PB vs Industry: 6657 is good value based on its PB Ratio (2.5x) compared to the TW Biotechs industry average (3.9x).
Future Growth
How is Energenesis BiomedicalLTD forecast to perform in the next 1 to 3 years based on estimates from 0 analysts?
Future Growth Score
0/6Future Growth Score 0/6
Earnings vs Savings Rate
Earnings vs Market
High Growth Earnings
Revenue vs Market
High Growth Revenue
Future ROE
124.8%
Forecasted Pharmaceuticals & Biotech industry annual growth in earnings
In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as Energenesis BiomedicalLTD has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.
This is quite a rare situation as 97% of companies covered by SimplyWall St do have past financial data.
Past Performance
How has Energenesis BiomedicalLTD performed over the past 5 years?
Past Performance Score
0/6Past Performance Score 0/6
Quality Earnings
Growing Profit Margin
Earnings Trend
Accelerating Growth
Earnings vs Industry
High ROE
-14.2%
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: 6657 is currently unprofitable.
Growing Profit Margin: 6657 is currently unprofitable.
Past Earnings Growth Analysis
Earnings Trend: 6657 is unprofitable, and losses have increased over the past 5 years at a rate of 14.2% per year.
Accelerating Growth: Unable to compare 6657's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: 6657 is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (-29%).
Return on Equity
High ROE: 6657 has a negative Return on Equity (-14.11%), as it is currently unprofitable.
Financial Health
How is Energenesis BiomedicalLTD's financial position?
Financial Health Score
6/6Financial Health Score 6/6
Short Term Liabilities
Long Term Liabilities
Debt Level
Reducing Debt
Stable Cash Runway
Forecast Cash Runway
Financial Position Analysis
Short Term Liabilities: 6657's short term assets (NT$740.0M) exceed its short term liabilities (NT$27.2M).
Long Term Liabilities: 6657's short term assets (NT$740.0M) exceed its long term liabilities (NT$6.2M).
Debt to Equity History and Analysis
Debt Level: 6657 is debt free.
Reducing Debt: 6657 has no debt compared to 5 years ago when its debt to equity ratio was 15.3%.
Balance Sheet
Cash Runway Analysis
For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: 6657 has sufficient cash runway for more than 3 years based on its current free cash flow.
Forecast Cash Runway: 6657 has sufficient cash runway for more than 3 years if free cash flow continues to reduce at historical rates of 13.3% each year
Dividend
What is Energenesis BiomedicalLTD current dividend yield, its reliability and sustainability?
Dividend Score
0/6Dividend Score 0/6
Notable Dividend
High Dividend
Stable Dividend
Growing Dividend
Earnings Coverage
Future Dividend Coverage
Dividend Yield vs Market
Notable Dividend: Unable to evaluate 6657's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.
High Dividend: Unable to evaluate 6657's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.
Stability and Growth of Payments
Stable Dividend: Insufficient data to determine if 6657's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if 6657's dividend payments have been increasing.
Earnings Payout to Shareholders
Earnings Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.
Cash Payout to Shareholders
Cash Flow Coverage: Unable to calculate sustainability of dividends as 6657 has not reported any payouts.
Next Steps
Management
How experienced are the management team and are they aligned to shareholders interests?
CEO
Han-min Chen
no data
Tenure
Dr. Han-min Chen is Co-Founder, Vice Chairman and General Manager at Energenesis Biomedical CO.,LTD. He has many years in the research of biomedicine, specializing in biochemistry and enzyme chemistry. He...
Ownership
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.
Ownership Breakdown
Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 11.7%.
Top Shareholders
Company Information
Energenesis Biomedical CO.,LTD.'s employee growth, exchange listings and data sources
Key Information
- Name: Energenesis Biomedical CO.,LTD.
- Ticker: 6657
- Exchange: TPEX
- Founded: 2012
- Industry: Biotechnology
- Sector: Pharmaceuticals & Biotech
- Implied Market Cap: NT$2.103b
- Shares outstanding: 66.54m
- Website: https://www.energenesis-biomedical.com
Number of Employees
Location
- Energenesis Biomedical CO.,LTD.
- No.21, Ln.583, Ruiguang Road
- 6F.-3, Neihu Dirstrict
- Taipei City
- 11492
- Taiwan
Listings
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2022/05/17 00:00 |
| End of Day Share Price | 2022/05/16 00:00 |
| Earnings | 2021/12/31 |
| Annual Earnings | 2021/12/31 |
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.